Document:

SCHEDULE

Tax covenant

		1.	Interpretation

		1.1	The definitions and rules of interpretation in this clause
apply in this Tax Covenant.

	Accounts Relief:	
        means : 

        a)    any
Relief (including the right to a repayment of Tax) that has been shown as an asset in the Accounts; and 

        b)    any
Relief that has been taken into account in computing (and so reducing or eliminating) any provision for deferred Tax in the Accounts; 

	Buyer's Relief:	
        means: 

        a)    any
Accounts Relief; 

        b)    any
Relief which arises in connection with any Event occurring after Accounts Date; and 

        c)    any
        Relief, whenever arising, of the Buyer or any member of the Buyer's Tax Group other than the Company;

	Buyer's Tax Group:	the Buyer and any other company or companies which are from time to time treated as members of the same group as, or otherwise connected or associated in any way with, the Buyer for any Tax purpose;
	Dispute:	any dispute, appeal, negotiations or other proceedings in connection with a Tax Claim;
	Event:	includes (without limitation), the expiry of a period of time, the Company becoming or ceasing to be associated with any other person for any Tax purpose or ceasing to be or becoming resident in any country for any Tax purpose, the death or the winding up or dissolution of any person, the earning, receipt or accrual for any Tax purpose of any income, profit or gains, the incurring of any loss or expenditure, and any transaction (including the execution and completion of all provisions of this agreement), event, act or omission whatsoever, and any reference to an Event occurring on or before a particular date shall include Events that, for Tax purposes, are deemed to have, or are treated or regarded as having, occurred on or before that date;

 

    	1

    	 

    

 

	Group Relief:	
        any or all of the following: 

        a)    relief
surrendered or claimed under Part 5 of the Corporation Tax Act 2010 (Chapter IV of Part X of ICTA 1988); 

        b)    advance
        corporation tax capable of being surrendered or claimed under regulation 13 of the Corporation Tax (Treatment of Unrelieved Surplus
        Advance Corporation Tax) Regulations 1999 (SI 1999/358);

        c)    a
Tax refund capable of being surrendered or claimed under section 963 of the Corporation Tax Act 2010 (section 102 of the Finance
Act 1989);

        d)    the
notional transfer of an asset or reallocation of a gain or loss under sections 171A or 179A of TCGA 1992 and the notional reallocation
of a gain under section 792 of the Corporation Tax Act 2009 (clause 66 of Schedule 29 to the Finance Act 2002 for accounting periods
ending before 1 April 2009);

        e)    eligible
unrelieved foreign Tax surrendered or claimed under the Double Taxation Relief (Surrender of Relievable Tax Within a Group) Regulations
2001 (SI 2001/1163); and

        f)    any
other Relief available between members of a group for Tax purposes;

	Liability for Taxation:	
        means:

        a)    any
liability of the Company to make an actual payment of or in respect of Tax whether or not the same is primarily payable by the
Company and whether or not the Company has or may have any right of reimbursement against any other person, in which case the
amount of the Liability for Taxation shall be the amount of the actual payment;

 

    	2

    	 

    

 

	 	
        

        b)    the
Loss of any Accounts Relief (including any Relief surrendered or to be surrendered by a member of the Seller's Group), in which
case the amount of the Liability for Taxation will be the amount of Tax which would (on the basis of Tax rates current at the
date of such Loss) have been saved but for such Loss, assuming for this purpose that the Company had sufficient profits or was
otherwise in a position to use the Relief; or where the Relief is the right to repayment of Tax or to a payment in respect of
Tax, the amount of the repayment or payment; and

        c)    the
        use or setting off of any Buyer's Relief in circumstances where, but for such set off or use, the Company would have had a liability
        to make a payment of or in respect of Tax for which the Buyer would have been able to make a claim against the Seller under this
        Tax Covenant, in which case, the amount of the Liability for Taxation shall be the amount of Tax for which the Seller would have
        been liable but for such set off or utilisation;

	Loss:	includes absence, failure to obtain, non-existence, non-availability, reduction, modification, loss, counteraction, nullification, utilisation, disallowance, withdrawal or claw-back for whatever reason;
	Overprovision:	
        the amount by which any provision
for tax (other than deferred tax) in the Accounts is overstated, except where such overstatement arises as a result of: 

        a)    a
change in law; 

        b)    a
change in the accounting bases on which the Company values its assets; or 

        c)    a
voluntary act or omission of the Buyer, 

        d)    which,
        in each case, occurs after Completion;

	Relief:	includes any loss, relief, allowance, credit, exemption or set off in respect of Tax or any deduction in computing income, profits or gains for the purposes of Tax and any right to a repayment of Tax or to a payment in respect of Tax;
	Saving:	the reduction or elimination of any liability of the Company to make an actual payment of corporation tax in respect of which the Seller would not have been liable under clause 2, by the use of any Relief arising wholly as a result of a Liability for Taxation in respect of which the Seller has made a payment under clause 2 of this Tax Covenant;

 

    	3

    	 

    

 

	Seller's Group:	the Seller and any other company or companies (other than the Company and any Subsidiaries) which either are or become after Completion, or have within the seven years ending at Completion been treated as, members of the same group, or otherwise connected or associated in any way with the Seller for Tax purposes;
	Tax or Taxation:	all forms of taxation and statutory, governmental, state, federal, provincial, local, government or municipal charges, duties, imposts, contributions, levies, withholdings or liabilities wherever chargeable and whether of the UK or any other jurisdiction (including, for the avoidance of doubt, National Insurance contributions in the UK and corresponding obligations elsewhere) and any penalty, fine, surcharge, interest, charges or costs relating thereto (including interest and penalties arising from the failure of the Company to make adequate instalment payments under the Corporation Tax (Instalments Payments) Regulations 1998 (SI 1998/3175) in any period ending on or before Completion);
	Tax Claim:	any assessment, notice, demand, letter or other document issued or action taken by or on behalf of any Taxation Authority, self-assessment or other occurrence from which it appears that the Company or the Buyer is or may be subject to a Liability for Taxation or other liability in respect of which the Seller is or may be liable under this Tax Covenant;
	Taxation Authority:	any government, state or municipality or any local, state, federal or other fiscal, revenue, customs or excise authority, body or official competent to impose, administer, levy, assess or collect Tax in the UK or elsewhere;
	Taxation Statute:	any directive, statute, enactment, law or regulation wherever enacted or issued, coming into force or entered into providing for or imposing any Tax and shall include orders, regulations, instruments, by-laws or other subordinate legislation made under the relevant statute or statutory provision and any directive, statute, enactment, law, order, regulation or provision which amends, extends, consolidates or replaces the same or which has been amended, extended, consolidated or replaced by the same.

 

    	4

    	 

    

 

		1.2	References to gross receipts, income, profits or gains earned, accrued or received shall include
any gross receipts, income, profits or gains deemed under the relevant Taxation Statute to have been or treated or regarded as
earned, accrued or received.

		1.3	References to a repayment of Tax shall include any repayment supplement or interest in respect
of it.

		1.4	Any reference to something occurring in the ordinary course of business shall not include:

		1.4.1	anything that involves, or leads directly or indirectly to, any liability of the Company to Tax
that is the primary liability of, or properly attributable to, or due from another person (other than a member of the Buyer's Tax
Group);

		1.4.2	anything that relates to or involves the acquisition or disposal of an asset or the supply of services
(including the lending of money, or the hiring or licensing of tangible or intangible property) in a transaction which is not entered
into on arm's length terms;

		1.4.3	anything that relates to or involves the making of a distribution for Tax purposes, the creation,
cancellation or reorganisation of share or loan capital, the creation, cancellation or repayment of any intra-group debt or the
Company becoming or ceasing to be or being treated as ceasing to be a member of a group of companies or becoming or ceasing to
be associated or connected with any other company for any Tax purposes;

		1.4.4	anything that relates to any scheme, transaction or arrangement designed partly or wholly or containing
steps or stages designed partly or wholly for the purpose of avoiding or reducing or deferring a Liability to Taxation;

		1.4.5	anything that gives rise to a Liability for Taxation on deemed (as opposed to actual) profits or
to the extent that it gives rise to a Liability for Taxation on an amount of profits greater than the difference between the sale
proceeds of an asset and the amount attributable to that asset in the Accounts or, in the case of an asset acquired since the Accounts
Date, the cost of that asset; or

		1.4.6	anything that involves, or leads directly or indirectly to, a change of residence of the Company
or any Subsidiary for Tax purposes.

 

    	5

    	 

    

 

		1.5	Unless the contrary intention appears, words and expressions defined in this agreement have the
same meaning in this Tax Covenant and any provisions in this agreement concerning matters of construction or interpretation also
apply in this Tax Covenant.

		1.6	Any stamp duty which is charged on any document, or in the case of a document which is outside
the UK, any stamp duty which would be charged on the document if it were brought into the UK, which is necessary to establish the
title of the Company to any asset, and any interest fine or penalty relating to such stamp duty, shall be deemed to be a liability
of the Company to make an actual payment of Taxation in consequence of an Event arising on the last day on which it would have
been necessary to pay such stamp duty in order to avoid any liability to interest or penalties arising on it.

		2.	Covenant

The Seller covenants with the
Buyer that, subject to the provisions of this Tax Covenant, the Seller shall pay to the Buyer an amount equal to any:

		2.1	Liability for Taxation resulting from or by reference to any Event occurring on or before Completion
or in respect of any gross receipts, income, profits or gains earned, accrued or received by the Company on or before Completion,
whether or not such liability has been discharged on or before Completion;

		2.2	Liability for Taxation, including liability for payments in respect of Taxation, which arises solely
as a result of the relationship for Tax purposes before Completion of the Company with any person other than a member of the Buyer's
Tax Group, whether arising before or after Completion;

		2.3	Liability for Taxation which arises as a result of any Event which occurs after Completion pursuant
to a legally binding obligation (whether or not conditional) entered into by the Company on or before Completion otherwise than
in the ordinary course of business;

		2.4	Liability for Taxation which arises after Completion but which relates to the periods prior to
Completion and arises as a result of the Company’s failure to account to the Taxation Authority for Tax on sums received
by way of gratuities or tips prior to Completion; and

		2.5	costs and expenses (including legal costs on a full indemnity basis), properly incurred by the
Buyer, the Company or any member of the Buyer's Tax Group in connection with any Liability for Taxation or other liability in respect
of which the Seller is liable under this Schedule, any Tax Claim or taking or defending any action under this Schedule.

 

    	6

    	 

    

 

		3.	Payment date and interest

		3.1	Payment by the Seller in respect of any liability under this Schedule must be made in cleared and
immediately available funds on the following days:

		3.1.1	in the case of a Liability for Taxation that involves an actual payment of or in respect of Tax,
the later of ten business days before the due date for payment and five business days after the date on which the Buyer serves
notice on the Seller requesting payment;

		3.1.2	in the case of the loss of a right to repayment of Tax or a liability under Clause 2 (d) five Business
Days following the date on which the Buyer serves notice on the Seller requesting payment;

		3.1.3	in a case that involves the loss of a Relief (other than a right to repayment of Tax), the last
date on which the Tax is or would have been required to be paid to the relevant Taxation Authority in respect of the earlier of:

		3.1.3.1	the period in which the Loss of the Relief gives rise to an actual liability to pay tax; or

		3.1.3.2.	the period in which the Loss of the Relief occurs (assuming for this purpose that the Company had
sufficient profits or was otherwise in a position to use the Relief); or

		3.1.3.3	in a case that falls within clause c) of the definition of Liability for Taxation, the date on
which the Tax saved by the Company or the relevant Subsidiary is or would have been required to be paid to the relevant Taxation
Authority.

		3.2	If the Liability for Taxation is a liability to corporation tax payable by instalments in accordance
with the Corporation Tax (Instalment Payments) Regulations 1998 (SI 1998/3175):

		3.2.1	the notice served by the Buyer on the Seller under clause 3.1 shall specify the amount of the liability
that is due for payment on each instalment date for the accounting period in which the Liability to Taxation arises; and

		3.2.2	the due dates for payment of the Tax clause 3.1.1 to clause 3.1.3 shall be the due dates for payment
of each of the instalments.

		3.3	Any dispute as to the amount specified in any notice served on the Seller under clause 3.1.1 to
clause 3.1.3 shall be determined by the auditors of the Company for the time being, acting as experts and not as arbitrators (the
costs of that determination being shared equally by the Seller and the Buyer).

		3.4	If any sums required to be paid by the Seller under this Tax Covenant are not paid on the date
specified in clause 3.1, then, except to the extent that the Seller's liability under clause 2 compensates the Buyer for the late
payment by virtue of it extending to interest and penalties, such sums shall bear interest (which shall accrue from day to day
after as well as before any judgment for the same) at the rate of 2% per annum over the base rate from time to time of the Bank
of England or (in the absence thereof) at such similar rate as the Buyer shall select from the day following the due date up to
and including the day of actual payment of such sums, such interest to be compounded quarterly.

 

    	7

    	 

    

 

		4.	Exclusions

		4.1	The covenant contained in clause 2 above shall not cover any Liability for Taxation to the extent
that:

		4.1.1	provision or reserve (other than a provision for deferred tax) in respect of the liability is made
or reflected in the Accounts;

		4.1.2	such Liability for Taxation was discharged on or before the Accounts Date and the discharge of
such Liability for Taxation was reflected in the Accounts;

		4.1.3	it arises or is increased as a result only of any change in the law of Tax (other than a change
targeted specifically at countering a tax avoidance scheme) announced and coming into force after Completion (whether relating
to rates of Tax or otherwise) or the withdrawal of any extra-statutory concession previously made by a Taxation Authority (whether
or not the change purports to be effective retrospectively in whole or in part);

		4.1.4	it would not have arisen but for a change after Completion in the accounting bases on which the
Company values its assets (other than a change made to comply with UK GAAP as at the date of Completion);

		4.1.5	the Buyer is compensated for any such matter under any other provision of this agreement;

		4.1.6	there is available to the Company a Relief which is not
a Buyer's Relief; or

		4.1.7	it would not have arisen but for a voluntary act, transaction or omission of the Company or the
Buyer outside the ordinary course of business after Completion and which the Buyer was aware or ought reasonably to have been aware
would give rise to the Liability for Taxation or other liability in question.

		4.2	For the purposes of clause 4.1.8 an act will not be regarded as voluntary if undertaken pursuant
to a legally binding obligation entered into by the Company on or before Completion or imposed on the Company by any legislation
whether coming into force before, on or after Completion or for the purpose of avoiding or mitigating a penalty imposable by such
legislation, or if carried out at the written request of the Seller.

 

    	8

    	 

    

 

		5.	Limitations

		5.1	The liability of the Seller under clause 2 will terminate on the seventh anniversary of Completion
except in respect of any claim under clause 2 under Schedule 4 of the Agreement of which notice in writing is given to the Seller
before that date containing, to the extent reasonably practicable, a description of such claim and the estimated total amount of
the claim.

		5.2	Subject to clause 5.3 and clause 5.4, the aggregate liability of the Seller under clause 2 shall
not exceed $3,150,000 USD.

		5.3	The amount of the aggregate liability of the Seller set out in clause 5.2 will be increased by
any amount received by the Seller by way of payment or set off under clause 6 (Overprovisions), clause 7 (Savings) or clause 8
(Recovery from third parties).

		5.4	The amount of the aggregate liability of the Seller set out in clause 5.2 will be increased by
the amount of any liability of the Seller arising (or which would have arisen but for clause 4) in respect of Taxation which is
primarily the liability of, or is attributable to, a person other than the Company.

		6.	Overprovisions

		6.1	If, on or before the seventh anniversary of Completion, the auditors for the time being of the
Company certify (at the request and expense of the Seller) that any provision for Tax in the Accounts (other than a provision for
deferred tax) has proved to be an Overprovision, then:

		6.1.1	the amount of any Overprovision shall first be set off against any payment then due from the Seller
under this Tax Covenant;

		6.1.2	to the extent that there is an excess, a refund shall be made to the Seller of any previous payment
or payments made by the Seller under this Tax Covenant (and not previously refunded under this Tax Covenant) up to the amount of
such excess; and

		6.1.3	to the extent that the excess referred to in clause 6.1.2 is not exhausted, the remainder of that
excess will be carried forward and set off against any future payment or payments which become due from the Seller under this Tax
Covenant.

		6.2	After the Company's auditors have produced any certificate under this clause 6, the Seller or the
Buyer may, at any time before the seventh anniversary of Completion, request the auditors for the time being of the Company to
review (at the expense of the Seller) that certificate in the light of all relevant circumstances, including any facts of which
it was not aware, and which were not taken into account, at the time when such certificate was produced, and to certify whether
in their opinion the certificate remains correct or whether, in light of those circumstances, it should be amended.

 

    	9

    	 

    

 

		6.3	If the auditors make an amendment to the earlier certificate and the amount of the Overprovision
is revised, that revised amount shall be substituted for the previous amount and any adjusting payment that is required shall be
made by or to the Seller (as the case may be) as soon as practicable.

		7.	Savings

If (at the Seller's request
and expense) the auditors for the time being of the Company determine that the Company has obtained a Saving, the Buyer shall
as soon as reasonably practicable thereafter repay to the Seller, after deduction of any amounts then due by the Seller, the lesser
of:

		7.1	the amount of the Saving (as determined by the auditors) less any costs incurred by the Buyer,
the Company; and

		7.2	the amount paid by the Seller under clause 2 in respect of the Liability for Taxation which gave
rise to the Saving less any part of that amount previously repaid to the Seller under any provision of this Tax Covenant or otherwise.

		8.	Recovery from third parties

		8.1	Where the Seller has paid an amount in full discharge of a liability under clause 2 in respect
of any Liability for Taxation and the Buyer, the Company is or becomes entitled to recover from some other person not being the
Buyer, the Company or any other company within the Buyer's Tax Group, any amount in respect of such Liability for Taxation, the
Buyer shall or shall procure that the Company shall:

		8.1.1	notify the Seller of its entitlement as soon as reasonably
practicable; and

		8.1.2	if required by the Seller and, subject to the Buyer and the Company being indemnified by the Seller
against any Tax that may be suffered on receipt of that amount and any costs and expenses incurred in recovering that amount, take
or procure that the Company takes all reasonable steps to enforce that recovery against the person in question (keeping the Seller
fully informed of the progress of any action taken) provided that the Buyer shall not be required to take any action under this
clause 8.1 (other than an action against:

		8.1.2.1	a Taxation Authority; or

		8.1.2.2	a person who has given Tax advice to the Company on or
before Completion),

which, in the Buyer's reasonable
opinion, is likely to harm its, the Company's commercial or employment relationship (potential or actual) with that or any other
person.

 

    	10

    	 

    

 

		8.2	If the Buyer or the Company recovers any amount referred to in clause 8.1, the Buyer shall account
to the Seller for the lesser of:

		8.2.1	any amount recovered (including any related interest or related repayment supplement) less any
Tax suffered in respect of that amount and any costs and expenses incurred in recovering that amount (except to the extent that
amount has already been made good by the Seller under clause 8.1 (b)); and

		8.2.2	the amount paid by the Seller under clause 2 in respect of the Liability for Taxation in question.

		9.	Surrender of Group Relief or other election

		9.1	Subject to and in accordance with the provisions of this clause 9 , if any liability of the Seller
under this Tax Covenant or in respect of any claim under the Tax Warranties can be reduced or eliminated by the surrender of Group
Relief to the Company by the Seller or any company other than a member of the Buyer's Tax Group or a company connected with the
Buyer (including by way of electing that any gain on the disposal or notional disposal of an asset be treated as accruing not to
the Company but to a member of the Seller's Group), the Seller may make or procure the making of such surrender or election and
the Buyer shall procure that the Company shall cooperate with the Seller in relation to such surrender or election and make all
necessary returns, claims, consents and notifications required to be made in respect of such surrender or election.

		9.2	The Company shall not be liable to give any consideration in respect of any surrender of or election
in relation to Group Relief under clause 9.1.

		10.	Corporation tax returns

		10.1	Subject to this clause 10, the Buyer will have exclusive conduct of all Taxation affairs of the
Company after Completion.

		10.2	The Buyer will procure that the Company keeps the Seller or the Seller's duly authorised agent
fully informed of its Taxation affairs in respect of any accounting period ended on or before Completion for which final agreement
with the relevant Taxation Authority of the amount of Taxation due from the Company has not been reached. The Buyer will not submit
any substantive correspondence or submit or agree any return or computation for any such period to any Taxation Authority without
giving the Seller a reasonable opportunity to comment and taking account of the Seller's reasonable representations.

		10.3	The Buyer will procure that the Company does not amend or withdraw any return or computation or
any claim, election, surrender or consent made by it in respect of its accounting periods ended on or before Completion without
giving the Seller a reasonable opportunity to comment and taking account of the Seller's reasonable representations.

 

    	11

    	 

    

 

		10.4	For the avoidance of doubt:

		10.4.1.	where any matter relating to Tax gives rise to a Tax Claim, the provisions of clause 11 shall take
precedence over the provisions of this clause 10; and

		10.4.2	the provisions of this clause 10 shall not prejudice the rights of the Buyer to make a claim under
this Tax Covenant in respect of any Liability for Taxation.

		11.	Conduct of Tax Claims

		11.1	Subject to clause 11.2, if the Buyer or the Company becomes aware of a Tax Claim, the Buyer shall
give or procure that notice in writing is given to the Seller or to the Seller's duly authorised agent as soon as reasonably practicable,
provided that the giving of such notice shall not be a condition precedent to the Seller's liability under this Tax Covenant.

		11.2	If the Seller becomes aware of a Tax Claim, it shall notify the Buyer in writing as soon as reasonably
practicable, and, on receipt of such notice, the Buyer shall be deemed to have given the Seller notice of the Tax Claim in accordance
with the provisions of clause 11.1.

		11.3	Subject to clause 11.4, if the Seller indemnifies the Buyer and the Company to the Buyer's reasonable
satisfaction against all liabilities, costs, damages or expenses which may be incurred thereby, including any additional Liability
for Taxation, the Buyer shall take and procure that the Company shall take such action as the Seller may reasonably request by
notice in writing given to the Buyer to avoid, dispute, defend, resist, appeal, request an internal HM Revenue and Customs review
or compromise any Tax Claim.

		11.4	Neither the Buyer nor the Company shall be obliged to appeal or procure an appeal against any assessment
to Tax if the Buyer, having given the Seller written notice of such assessment, does not receive written instructions from the
Seller within ten business days to do so.

		11.5	If:

		11.5.1	the Seller does not request the Buyer to take any action under clause 11.2 or fails to indemnify
the Buyer or the Company to the Buyer's reasonable satisfaction within a period of time (commencing with the date of the notice
given to the Seller) that is reasonable having regard to the nature of the Tax Claim and the existence of any time limit in relation
to avoiding, disputing, defending, resisting, appealing, seeking a review or compromising such Tax Claim, and which period will
not in any event exceed a period of 14 days;

 

    	12

    	 

    

 

		11.5.2	the Seller (or the Company before Completion) has been involved in a case involving fraudulent
conduct or deliberate default in respect of the Liability for Taxation which is the subject matter of the Dispute; or

		11.5.3	the Dispute involves an appeal against a determination by the Tax Chamber of the First-tier Tribunal
or higher tribunal, unless the Seller has obtained the opinion of Tax counsel of at least ten years' standing that there is a reasonable
prospect that the appeal will succeed,

		11.5.4	the Buyer or the Company shall have the conduct of the Dispute absolutely (without prejudice to
its rights under this Tax Covenant) and shall be free to pay or settle the Tax Claim on such terms as the Buyer or the Company
may in its absolute discretion consider fit.

		11.6	Neither the Buyer nor the Company shall be subject to any claim by or liability to the Seller for
non-compliance with any of the provisions of this clause 11 if the Buyer, the Company or the relevant Subsidiary has acted in good
faith in accordance with the instructions of the Seller.

		12.	Grossing up

		12.1	All sums payable by the Seller to the Buyer under this Tax Covenant shall be paid free and clear
of all deductions or withholdings whatsoever unless the deduction or withholding is required by law. If any deductions or withholdings
are required by law to be made from any of the sums payable under this Tax Covenant, the Seller shall pay to the Buyer such sum
as will, after the deduction or withholding has been made, leave the Buyer with the same amount as it would have been entitled
to receive in the absence of any such requirement to make a deduction or withholding.

		12.2.	If the Buyer incurs a taxation liability which results from, or is calculated by reference to,
any sum paid under this Tax Covenant, the amount so payable shall be increased by such amount as will ensure that, after payment
of the taxation liability, the Buyer is left with a net sum equal to the sum it would have received had no such taxation liability
arisen.

		12.3	If the Buyer would, but for the availability of a Buyer's Relief, incur a taxation liability falling
within clause 12.2, it shall be deemed for the purposes of that CLAUSE to have incurred and paid that liability.

		12.4	If the Buyer assigns the benefit of this Tax Covenant or this agreement the Seller shall not be
so liable under clause 12.1 or 12.2 except to the extent that the Seller would have been so liable had no such assignment occurred.

 

    	13

    	 

    

 

		13.	General

All payments made by the Seller
to the Buyer or by the Buyer to the Seller in accordance with this Tax Covenant will be treated, to the extent possible, as an
adjustment to the Purchase Price for the Sale Shares.

 

    	14Celsus Therapeutics Plc

 

October 23, 2013

 

Pablo Jimenez

166 South Street

Rockport, MA 01966 USA

 

Dear Pablo:

 

We are pleased to confirm the following
terms in connection with your employment with Celsus Therapeutics Plc (the “Company”)1/.

 

		1.	Position and Reporting. You will serve as the Company’s Chief Medical Officer. You will be required to travel
to the Company’s New York location, and such other places as is necessary in connection with your performance of your responsibilities
hereunder. You will report to the Company’s Chief Executive Officer (the “CEO”), or any such other person
designated by the Company.

 

		2.	Duties. Your responsibilities will include, but not be limited to: general supervision and control over, and responsibility
for, the Company’s pre-clinical and clinical development activities; regulatory development, planning, and filings; and Company
clinical presentations and development plan and strategy.  In addition to your primary duties, you shall: (a) manage and direct
all aspects of drug development  and clinical operations including, Phases 1-3 clinical development and clinical trials; (b)
be responsible for the development and commercialization of  the Company’s technology related to the treatment of inflammatory
diseases; (c) design, draft, execute, reports on toxicology, pharmacology and Phase 1–3 clinical trials; (d) work with third
party clinical sites, contract researchers and organizations, advisors, and consultants; (e) draft, develop, strategize for, prepare,
and submit regulatory applications and present at regulatory meetings; (f) establish a strong relationship
and credibility with biotechnology and healthcare analysts  and numerous health care fund managers; (g) establish licensing
partners and participate in industry collaboration; (h) present development updates in conference calls and in meetings with shareholders
and potential investors; (i) help build shareholder value through investor meetings and presentations; and (j) such other
duties and responsibilities as may be assigned to you from time to time by the CEO, and/or Executive Chairman, and/or the Company’s
Board of Directors (the “Board”). You shall devote your full business time and attention to the performance
of your duties to the Company.

 

 

 

1/        It
is anticipated that the Company may in the future will re-organize under Delaware law and it is intended that any reference to
the Company in this letter agreement includes the Company as so re-organized.

 

    	 

    	 

    

 

		3.	Start Date and Assurances. Your employment with the Company shall begin on October 23, 2013 (the “Start Date”).
You represent that (i) you are not a party to any agreement that would prohibit you from entering into employment with the Company;
(ii) no trade secret or proprietary information belonging to any previous employer will be disclosed by you at the Company and
that no such information, whether in the form of documents (electronic or otherwise), memoranda, software, etc., will be retained
by you or brought with you to the Company; and (iii) you have brought to the Company’s attention and provided it with a copy
of any agreement that may impact your future employment with the Company or performing the services contemplated, including but
not limited to any non-disclosure, non-competition, non-solicitation or invention assignment agreements containing future work
restrictions. You represent that prior to the Start Date you will not take any actions on behalf of the Company or engage in any
discussions or communications on behalf of the Company, including, without limitation, with any prospective Company employees or
other service providers.

 

		4.	Compensation. You will be entitled to an annual base salary (“Base Salary”)
at the rate of $240,000, which Base Salary shall accrue day to day, be subject to required holdings and paid in accordance with
the Company’s normal payroll practices applicable to similarly situated employees. The Base Salary will be reviewed annually
and may be increased from time to time at the sole discretion of the Company.

 

		5.	Annual Milestone Bonus. At the sole discretion of the Board
upon recommendation by the Compensation Committee (the “Compensation Committee”), following each calendar year
of employment, you shall be eligible to receive a cash bonus of up to twenty-five percent (25%) of your Base Salary (the “Annual
Milestone Bonus”), based on your attainment of certain clinical development, and/or business milestones over the course
of the next sixteen (16) months as follows: execution and completion of first interpretable results of a Phase II atopic
dermatitis trial, IND filing/acceptance, and a financing round(s)  (the “Milestones”).
The determination of whether you have met the Milestones, and if so, the bonus amount (if any) that will be paid, shall be determined
by the Board in its sole and absolute discretion. You must remain employed by the Company through and including the Milestones
in order to be eligible to earn or receive any Annual Milestone Bonus for that year. Any Annual Milestone Bonuses shall be paid
in cash as either single lump-sum payment or in installments over a period not to exceed 6 months, as determined by the Board,
but in no event later than March 15 of the calendar year following the calendar year in which the Milestone was achieved. 

 

		6.	Stock Options. Subject to approval by the Board and subject
to the terms of the Company’s 2007 Stock Incentive Plan (the “Plan”), as soon as practicable
following the Start Date, you will be granted an option to purchase One Hundred Thirty Thousand (130,000) shares of the Company’s
ESOP Plan (the “Option”). On each anniversary of the effective grant date of the Option, one-fourth of the shares
subject to the Option shall vest, subject to your continued employment with the Company on each such vesting date. The Option will
be governed by the Plan and shall be granted pursuant to a separate stock option grant notice and stock option agreement. The exercise
price per share of the Option will be equal to the fair market value of a single share of Common Stock on the effective date of
the grant upon approval by the Board pursuant to the Plan. You will be granted options to purchase an additional Seventy Thousand
(70,000) shares of the Company’s Common Stock subject to your attainment of certain clinical development, and/or business
milestones over the course of the next sixteen (16) months as follows: execution and completion of first interpretable results
an atopic dermatitis trial, and IND filing/acceptance.

 

		7.	Employee Benefits. You will be entitled to participate in the various group health, disability
and other welfare plans (“Benefit Plans”) and other employee programs, including sick and vacation time, as
generally are offered to similarly situated employees from time to time. With respect to vacation, you will be entitled to 4 weeks
of vacation per year subject to applicable Company policies.  Up to 1 week of vacation may be carried forward for the subsequent
year.

 

    	2

    	 

    

 

		8.	Expenses. You shall be reimbursed by the Company for all reasonable and necessary business
expenses actually incurred by you in performing your duties hereunder. In addition, the Company will (a) reimburse you in an amount
up to $100.00 per month (which amount shall be pro-rated for any partial months of employment based on the number of days employed
in the month) for routine, domestic mobile phone charges, provided you submit documentation supporting the charges, and (b) reimburse
you for the fees for your membership in the American College of Physicians. All reimbursements will be made in accordance with
policies established by the Company from time to time and subject to receipt by the Company of appropriate documentation supporting
the expenses. All expense reimbursements shall be paid as soon as administratively practicable. If an expense reimbursement is
not exempt from Section 409A of the Internal Revenue Code, the following rules apply: (i) in no event shall any reimbursement be
paid after the last day of the taxable year following the taxable year in which the expense was incurred; (ii) the amount of reimbursable
expenses incurred in one tax year shall not affect the expenses eligible for reimbursement in any other tax year; and (iii) the
right to reimbursement for expenses is not subject to liquidation or exchange for any other benefit.

 

		9.	Company Credit Card. If you are issued a Company credit card, you must (a) take good care if the card and immediately
report any loss of it to the CEO or the Chairman of the Board, (b) use it for business expenses in accordance with Company policy,
and (c) return it immediately to the Company upon request.

 

		10.	Employment Verification. Pursuant to federal law, this offer of employment is conditioned on your ability to provide
satisfactory proof of your eligibility to work in the United States within three days of your first day of work.

 

		11.	Company NDA. As a condition of your employment with the Company, you will be required to
execute the Celsus Therapeutics Plc Confidentiality, Intellectual Property, Non-Competition, and Non-Solicitation Agreement (the
“NDA”), attached hereto as Attachment A.

 

		12.	Nondisparagement. You agree that you will not, whether during your employment or thereafter,
directly or indirectly, make or ratify any statement, public or private, oral or written, to any person that disparages, either
professionally or personally, the Company or any of its affiliates, past and present, and each of them, as well as its and their
trustees, directors, officers, members, managers, partners, agents, attorneys, insurers, employees, stockholders, representatives,
assigns, and successors, past and present, and each of them.

 

		13.	Confidentiality. You will maintain the confidentiality of this letter agreement (and any related understandings, including
your compensation arrangements and amounts) at all times and will not discuss such matters with any person other than your spouse,
accountant, financial and tax advisors or attorney, except that you may make such disclosure (a) to the extent necessary with respect
to any litigation, arbitration or mediation involving this letter agreement, or (b) when disclosure is required by law or by any
court or arbitrator with apparent jurisdiction to order you to disclose or make accessible any information.

 

		14.	At-Will Employment. Your employment with the Company is “At-Will.” This means that, subject to the “Notice
Entitlement” paragraph below, you and the Company each have the right to terminate your employment at any time, for any reason.
This letter is not a contract of employment and is not to be construed or interpreted as containing any guarantee of continued
employment or employment for any definite period of time. Accordingly, the recitation of certain time periods in this letter is
solely for the purpose of defining your compensation and benefits. This letter also is not to be construed or interpreted as containing
any guarantee of any particular level or nature of compensation or benefits, and the level or nature of compensation or benefits
may be terminated or modified by the Company at any time without or without notice.

 

    	3

    	 

    

 

		15.	Notice Entitlement. The Company may terminate your employment with or without Cause. The period of notice that we will
give you to terminate your employment without Cause (and other than due to your death or Disability) is 3 months. The Company may
terminate your employment for Cause without notice. You must provide the Company with 3 months notice of your resignation for any
reason. We reserve the right to require you to not be in the Company’s offices and/or not to undertake all or any of your
duties and/or not to contact Company vendors, clients, colleagues or advisors (unless otherwise instructed) during all or part
of any period of notice of your termination of service or resignation. During any such period, you remain a service provider to
the Company with all duties of fidelity and confidentiality to the Company and subject to all terms and conditions of your employment
and should not be employed or engaged in any other business. Notwithstanding the foregoing, we reserve the right to pay you in
lieu of notice on a termination without Cause or, in the event of your resignation, terminate you immediately or at any time during
the notice period and pay you in lieu thereof without the requirement that you perform services for the Company.

 

This letter and the NDA reflect the entire agreement regarding
the terms and conditions of your employment. Accordingly, it supersedes and completely replaces any prior oral or written communication
on this subject. This letter agreement may not be modified, amended or waived unless in a writing signed by both parties. This
letter agreement shall inure to the benefit of the successors or general assigns of the Company. This letter agreement is non-assignable
except as provided herein. This letter agreement shall be governed by, interpreted and construed in accordance with the laws of
the State of New York without regard to any state’s principles of conflicts of laws.

 

We look forward to having you join the Company.

 

If you agree with the foregoing, please sign this letter in
the space provided below and return the original executed copy.

 

	Celsus Therapeutics Plc	 
	 	 
	By:	  /s/ Gur Roshwalb	 
	Name: Gur Roshwalb	 
	Title: President	 
	 	 	 
	By:	  /s/ Mark Cohen	 
	Name: Mark Cohen	 
	Title: Executive Chairman	 
	 	 
	Pablo Jimenez	 
	 	 
	   /s/ Pablo Jimenez	 

 

    	4

    	 

    

 

Additional Definitions

 

“Cause”
means a termination of your employment because you: (i) breached or failed to perform your obligations to the Company, including
the obligations in the NDA; (ii) engaged in conduct that causes or is reasonably expected to cause harm to the Company or your
professional reputation, monetarily or otherwise; (iii) are indicted or convicted of any criminal conduct (or than a moving infraction)
or are found to be in violation of any regulation relating to insider dealing trading, or you breach of the code on directors’
dealings in listed securities adopted from time to time by the Company or any affiliate of the Company; (iv) failed to perform
or are, in the reasonable opinion of the Board, incapable of properly performing your duties to the Company, if you have been given
due warning in writing by the Company of your poor performance or incapability and have failed within the specified period to meet
the required standard; or (v) wilfully neglected or refused to discharge your duties or to attend to the business of the Company.

 

“Disability”
means a physical or mental impairment that has rendered you unable to perform the essential functions of your employment, even
with reasonable accommodation that does not impose an undue hardship, for more than 90 consecutive calendar days, unless a longer
period is required by applicable law, in which case that longer period would apply. The determination of whether or not a Disability
exists for purposes of this letter agreement shall be made by the Company upon receipt and in reliance on competent medical advice
from one or more individuals, selected by the Company, who are qualified to give such professional medical advice.

 

    	5

    	 

    

 

ATTACHMENT A

 

Celsus
Therapeutics Plc

 

Confidentiality,
Intellectual Property, Non-Competition and Non-Solicitation Agreement

 

This Confidentiality, Intellectual Property, Non-Competition
and Non-Solicitation Agreement (“Agreement”) is made as of the Start Date (as defined below) between Celsus
Therapeutics Plc (collectively with its parents, subsidiaries and affiliates, the “Company”), and Pablo Jimenez,
an individual, (the “Employee”).

 

WHEREAS, the Company
desires to employ the Employee and the Employee desires to be employed by the Company on the terms contained in that certain offer
letter dated as of October 23, 2013 (the “Offer Letter”) with this Agreement, pursuant to which the Employee’s
employment with the Company will commence on the Start Date (as defined in the Offer Letter);

 

WHEREAS, as a condition
of employing Employee as set forth in the Offer Letter, the Company requires that the Employee enter into this Agreement;

 

NOW, THEREFORE,in consideration
of the mutual covenants and agreements herein contained, including without limitation the Company’s employment of the Employee
and the compensation s/he will receive in connection with his/her employment, and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.           Confidential
Information. As used in this Agreement, “Confidential Information” means any
and all data, information, conceptions, know-how, materials, intellectual property and their rights thereof, in whatever form including
and without limitation to include, any and all information relating to the Company’s current and future business activities,
products, regulatory, technology, business, including, without limitation, financial information, reports, and forecasts; regulatory
information, sales projections; inventions, improvements and other intellectual property, results, reports, trade secrets; data,
know-how; designs, algorithms, methods, processes, treatments, conceptions, compositions, materials, formulations or formulae;
software; market or sales information or plans; customer lists (including identity, customer contact information, preferences and
purchase history); vendors (including identity, contact information, pricing and services); business plans, prospects and opportunities
(such as possible acquisitions or dispositions of businesses or facilities); current and future business expansion plans and opportunities;
pricing and pricing strategies; licensee, licensor information, and the terms and conditions of any license agreement and employee
information, which is disclosed to Employee by or on behalf of the Company and/or is otherwise acquired by the Employee. Confidential
Information also includes, without limitation, information developed, resulting from, and/or generated by the Employee in the course
of the Employee’s employment by the Company, as well as other information to which the Employee may have access in connection
with his/her employment. Confidential Information also includes the confidential information of others with which the Company has
a business relationship. Notwithstanding the foregoing, Confidential Information does not include: (a) information which now or
in the future comes into the public domain, unless due to breach of the Employee’s duties under Section 2; (b) information
which is disclosed to Employee by others who are not, to Employee’s knowledge, under obligation of non-disclosure to the
Company; or (c) information which is disclosed by the Company to others without obligation of confidentiality.

 

    	A-1

    	 

    

 

2.           Confidentiality.
At all times, both during the Employee’s employment with the Company and after its termination, the Employee will keep in
confidence and trust all Confidential Information, and will not use, transfer, or disclose for his/her own benefit or the benefit
of any other Person any such Confidential Information without the written consent of the Company, except as may be necessary in
the ordinary course of performing the Employee’s duties to the Company.

 

3.           Documents,
Records, Etc. All documents, materials, records, files, communications, images, data, apparatus, equipment and other physical
property, whether or not pertaining to Confidential Information and in whatever form (electronic or otherwise), which are furnished
to the Employee by the Company or are produced by the Employee in connection with the Employee’s employment will be and remain
the sole and exclusive property of the Company. The Employee will return to the Company all such materials and property as and
when requested by the Company. In any event, the Employee will return all such materials and property immediately upon termination
of the Employee’s employment for any reason. The Employee will not retain any such material or property or any copies thereof
after the termination of his/her employment.

 

4.           No
Competition. From the Start Date through the end of the six-month period following the termination
of the Employee’s employment (the “Termination Date”), whether such termination is voluntary or involuntary
and regardless of the reason for the termination, (the “Restricted Period”) the Employee will not, directly
or indirectly, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage, prepare to
engage, participate, solicit, assist or invest in any Competing Business located in any geographic area in which the Company (i)
does business, distributes its products, or provides its services as of the Termination Date, or (ii) actively pursued a business,
development, or expansion opportunity, prior to the Termination Date. Notwithstanding the foregoing, (i) the Employee may own up
to 2% of the outstanding stock of a publicly held corporation which constitutes or is affiliated with a Competing Business, (ii)
the Employee may provide strategic advice outside of working hours to Qara Bio-Pharmaceutical Solutions, LLC provided that any
such strategic advice does not relate to any Competing Business and (iii) the Employee may work in a clinical medical practice
for up to one (1) morning of one (1) day per week, so long as Employee is not involved with or assisting such Competing Business,
and so long as Employee does not breach his/her obligations regarding Confidential Information.

 

5.           No
Solicitation. During the Restricted Period, the Employee shall not, directly or indirectly, take any of the following actions,
and, to the extent the Employee owns, manages, operates, controls, is employed by or participates in the ownership, management,
operation or control of, or is connected in any manner with, any business, the Employee shall use his/her best efforts to ensure
that such business does not take any of the following actions:

 

(a)          persuade
or attempt to persuade any Customer, Prospective Customer or Supplier to cease doing business with the Company, or to reduce the
amount of business it does with the Company;

 

(b)          solicit
or service for himself/herself or for any Person the business of a Customer, Prospective Customer or Supplier in order to provide
goods or services that are competitive with the goods and services provided by the Company;

 

(c)          persuade
or attempt to persuade any Service Provider to cease providing services to the Company; or

 

(d)          solicit
for hire or hire for himself/herself or for any third party any Service Provider.

 

    	A-2

    	 

    

 

(e)          The
following definitions are applicable to Section 4 and this Section 5:

 

(i)          “Competing
Business” means any business that is in the business of developing, manufacturing or marketing anti-inflammatory agents,
compounds or methods, and any other business in which the Company becomes engaged following the Start Date.

 

(ii)         “Customer”
means any Person that purchased goods or services from the Company at any time within 2 years prior to the date of the solicitation
prohibited by Section 5(a) or (b).

 

(iii)        “Prospective
Customer” means any Person with whom the Company met or to whom the Company presented for the purpose of soliciting the Person
to become a Customer of the Company within 12 months prior to the date of the solicitation prohibited by Section 5(a) or (b).

 

(iv)        “Service
Provider” means any Person who is an employee or independent contractor of the Company or who was within twelve (12) months
preceding the solicitation prohibited by Section 5(c) or (d) an employee or independent contractor of the Company.

 

(v)         “Supplier”
means any Person that sold goods or services to the Company at any time within twelve (12) months prior to the date of the solicitation
prohibited by Section 5(a) or (b).

 

(vi)        “Person”
means an individual, a sole proprietorship, a corporation, a limited liability company, a partnership, an association, a trust,
or other business entity, whether or not incorporated.

 

6.           Intellectual
Property.

 

(a)          All
Confidential Information, information, creations, data, documents, records, results, reports, discoveries, inventions, ideas, conceptions,
designs, software, improvements, enhancements, methods, processes, compositions, materials, formulas, formulations, trade secrets,
treatments, analyses, data rights, know-how, copyrightable materials, trademarks, and other technology and rights (and any related
improvements or modifications), whether or not subject to patent or copyright protection (collectively, “Creations”),
relating to any activities of the Company which were, are, or will be conceived by the Employee and/or developed and/or generated
and/or derived by the Employee in the course of and/or in connection with his/her employment or other services with the Company
and/or resulting from and/or arising under Employees employment and/or Confidential Information, whether conceived alone or with
others and whether or not conceived or developed during regular business hours, and if based on or resulting from Confidential
Information, also after the termination of the Employee’s employment, shall be the sole and exclusive property of the Company
and, to the maximum extent permitted by applicable law, shall be deemed “works made for hire” as that term is used
in the United States Copyright Act. The Employee agrees to and shall assign and will assign to the Company, without any further
compensation, all Creations conceived or developed from the start of this employment with the Company through to the Termination
Date, and after the Termination Date if the Creation incorporates and/or is based on and/or resulting from any Confidential Information.
All Creations shall be treated by Employee as Company’s Confidential Information.

 

    	A-3

    	 

    

 

(b)          To
the extent, if any, that the Employee retains any right, title or interest with respect to any Creations delivered to the Company
or related to his/her employment with the Company, the Employee hereby assigns and will assign to the Company, and grants to the
Company an irrevocable, paid-up, transferable, sub-licensable, worldwide right and license: (i) to modify all or any portion of
such Creations, including, without limitation, the making of additions to or deletions from such Creations, regardless of the medium
(now or hereafter known) into which such Creations may be modified and regardless of the effect of such modifications on the integrity
of such Creations; and (ii) to identify the Employee, or not to identify him/her, as one or more authors of or contributors to
such Creations or any portion thereof, whether or not such Creations or any portion thereof have been modified. The Employee further
waives any “moral” rights, or other rights with respect to attribution of authorship or integrity of such Creations
that s/he may have under any applicable law, whether under copyright, trademark, unfair competition, defamation, right of privacy,
contract, tort or other legal theory

 

(c)          The
Employee will promptly inform and transfer to the Company of any Creations. The Employee will also allow the Company to inspect
any Creations s/he conceives or develops within one (1) year after the termination of his/her employment for any reason to determine
if they are based on Confidential Information. The Employee shall (whether during his/her employment or after the termination of
his/her employment) execute such written instruments and do other such acts as may be necessary in the opinion of the Company or
its counsel to secure the Company’s rights in the Creations, including obtaining a patent, registering a copyright, or otherwise
(and the Employee hereby irrevocably appoints the Company and any of its officers as his/her attorney in fact to undertake such
acts in his/her name). The Employee’s obligation to execute written instruments and otherwise assist the Company in securing
its rights in the Creations will continue after the termination of his employment for any reason. The Company shall reimburse the
Employee for any out-of-pocket expenses (but not attorneys’ fees) s/he incurs in connection with his/her compliance with
this Section 6(c).

 

7.           Acknowledgement.
The Employee understands that the restrictions set forth in this Agreement are intended to protect the Company’s interest
in its Confidential Information, goodwill and established employee and customer relationships, and agrees that such restrictions
are reasonable and appropriate for this purpose.

 

8.           Disputes.

 

(a)          The
Employee agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the
Employee of the promises set forth in this Agreement, and that in any event, money damages would be an inadequate remedy for any
such breach. Accordingly, if the Employee breaches, or proposes to breach, any term of this Agreement, the Company shall be entitled,
in addition to all other remedies that it may have, to a temporary and preliminary injunction or other appropriate equitable relief
to restrain any such breach without showing or proving any actual damage to the Company from any court having competent jurisdiction
over the Employee.

 

(b)          The
parties agree to resolve any dispute arising under or relating to this Agreement before the United States District Court or the
state courts of the Commonwealth of Massachusetts encompassing Boston, and hereby consent to the exclusive jurisdiction of such
courts. Accordingly, with respect to any such court action, the Employee and the Company each: (i) submits to the personal jurisdiction
of these courts; (ii) consents to service of process under the notice provisions set forth in Section 9(a); (iii) waives any other
requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process;
and (iv) waives any objection to jurisdiction based on improper venue or improper jurisdiction.

 

(c)          BOTH
THE COMPANY AND THE EMPLOYEE HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE FEDERAL OR
STATE LAW.

 

    	A-4

    	 

    

 

(d)          The
Company shall be entitled to reasonable attorneys’ fees and costs in connection with any action filed under this Section
if it prevails in such action.

 

9.           Miscellaneous.

 

(a)          Notices.
Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered
in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return
receipt requested, to the Employee at the last address the Employee has filed in writing with the Company or, in the case of the
Company, at its main offices, attention of the Chief Executive Officer.

 

(c)          Validity.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other
provision of this Agreement, which shall otherwise remain in full force and effect. Moreover, if any one or more of the provisions
contained in this Agreement is held to be excessively broad as to duration, scope or activity, such provisions shall be construed
by limiting and reducing them so as to be enforceable to the maximum extent compatible with applicable law.

 

(d)          Waivers.
The waiver by the Company or the Employee of any right under this Agreement or of any failure to perform or any breach by the other
shall not be deemed a waiver of any other right under this Agreement or of any other failure or any other breach by such party,
whether of the same or a similar nature or otherwise. No waiver shall be deemed to have occurred unless set forth in writing executed
by or on behalf of the waiving party. No such written waiver shall be deemed a continuing waiver unless specifically stated therein,
and each such waiver shall operate only as to the specific term or condition waived and shall not constitute a waiver of such term
or condition for the future or as to any act other than that specifically waived.

 

(e)          Governing
Law. This agreement shall be governed by and construed in accordance with the laws of New York without regard to any state’s
principles of conflicts of law.

 

(f)          Successors;
Binding Agreement. This Agreement and the rights and obligations of the Company and the Employee under this Agreement shall
inure to each party’s benefit and to the benefit of each party’s respective heirs, personal representatives, successors
and assigns. The Employee specifically agrees that the Company may assign this Agreement to any successor.

 

(g)          Entire
Agreement. This Agreement sets forth the entire agreement and understanding of the Company and the Employee with respect of
its subject matter, and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or
warranties, whether oral or written, by any officer, executive or representative of either party in respect of said subject matter.

 

(i)          Headings
Descriptive. The headings of the Sections of this Agreement are inserted for convenience only and shall not in any way affect
the meaning or construction of this Agreement.

 

(j)          Capacity.
The Employee represents and warrants that s/he is not a party to any agreement that would prohibit her/him from entering into this
Agreement or performing fully his/her obligations under this Agreement.

 

WHEREFORE, the parties have executed this
Agreement effective on the date and year first above written.

 

    	A-5

    	 

    

 

	 	CELSUS THERAPEUTICS PLC
	 	 
	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 
	 	EMPLOYEE
	 	 
	 	 
	 	Pablo Jimenez

 

    	A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]